TKT Appoints Theresa Heggie as General Manager, Europe
February 04 2005 - 9:15AM
PR Newswire (US)
TKT Appoints Theresa Heggie as General Manager, Europe CAMBRIDGE,
Mass., Feb. 4 /PRNewswire-FirstCall/ -- Transkaryotic Therapies,
Inc. (NASDAQ:TKTX) announced today the appointment of Theresa
Heggie, formerly Vice President Global Marketing for the Anesthesia
and Critical Care business unit of Baxter Healthcare, to the new
position of General Manager, TKT Europe. "Theresa has a proven
commercial and European track record and we are delighted to
welcome her to our organization. Her experience will be valuable to
us as she assumes leadership of the TKT team that launched Replagal
in Europe, and then achieved consistent sales growth over the past
three years. They have marketed Replagal with an emphasis on the
science and innovative services for physicians and patients and
established an important platform in Europe for our new product
launches. As we look to introduce additional lysosomal storage
disease products into the franchise, we intend to build on this
strong foundation," said Dr. David Pendergast, Chief Operating
Officer of TKT. Ms. Heggie joins TKT Europe with over 20 years of
healthcare experience both in the United States and overseas. Early
in her career she held sales representative positions at Dow
Chemical and Janssen Pharmaceutical before assuming a variety of
marketing positions of increasing responsibility at Ohmeda
Pharmaceutical Products Division (PPD) from 1991 to 1998. At
Ohmeda, Ms. Heggie directed the U.S. launch of Suprane, an inhaled
anesthetic and the pre-marketing plan for inhaled nitric oxide for
the treatment of persistent pulmonary hypertension in newborns.
Following the 1998 acquisition of Ohmeda PPD by Baxter, Ms. Heggie
was named Vice President Anesthesia and Critical Care, Europe, a
business unit of Baxter's Medication Delivery Division, where she
had responsibility for marketing, sales, medical and regulatory
affairs, finance and logistics. At the end of her thirteen-year
tenure at Baxter (Ohmeda), Ms. Heggie held the position Vice
President, Global Marketing of the Anesthesia and Critical Care
business unit and was responsible for the establishment and
management of their global marketing function, including strategic
planning and life cycle management for several key products. Ms.
Heggie, aged 44, received a B.Sc. from Cornell University. About
TKT Transkaryotic Therapies, Inc. is a biopharmaceutical company
primarily focused on researching, developing and commercializing
treatments for rare diseases caused by protein deficiencies. Within
this focus, the company markets Replagal(TM), an enzyme replacement
therapy for Fabry disease, and is developing treatments for Hunter
syndrome and Gaucher disease. In addition to its focus on rare
diseases, TKT intends to commercialize Dynepo(TM), its Gene-
Activated(R) erythropoietin product for anemia related to kidney
disease, in the European Union. TKT was founded in 1988 and is
headquartered in Cambridge, Massachusetts, with additional
operations in Europe, Canada and South America. Additional
information about TKT is available on the company's website at
http://www.tktx.com/. This press release contains forward-looking
statements regarding TKT's management structure, as well as
statements containing the words "believes," "anticipates," "plans,"
"expects," "estimates," "intends," "should," "could," "will,"
"may," and similar expressions. There are a number of important
factors that could cause the company's actual results to differ
materially from those indicated by such forward-looking statements,
including, whether TKT will be able to successfully manage its
European operations; ability to launch new products in Europe and
other factors set forth under the caption "Certain Factors Which
May Affect Future Results" in the company's Quarterly Report on
Form 10-Q for the quarter ended September 30, 2004, which is on
file with the Securities and Exchange Commission and are
incorporated herein by reference. While the company may elect to
update forward-looking statements at some point in the future, the
company specifically disclaims any obligation to do so, even if its
expectations change. Gene-Activated(R) is a registered trademark
and Replagal(TM) is a trademark of Transkaryotic Therapies, Inc.
Dynepo(TM) is a trademark of Sanofi-Avenits. Suprane(R) is a
registered trademark of Baxter. For More Information Contact:
Justine E. Koenigsberg Senior Director, Corporate Communications
(617) 349-0271 Daniella M. Lutz Corporate Communications Manager
(617) 349-0205 http://www.newscom.com/cgi-bin/prnh/19990913/TKTLOGO
http://photoarchive.ap.org/ DATASOURCE: Transkaryotic Therapies,
Inc. CONTACT: Justine E. Koenigsberg, Senior Director, Corporate
Communications, +1-617-349-0271; or Daniella M. Lutz, Corporate
Communications Manager, +1-617-349-0205 both of Transkaryotic
Therapies, Inc. Web site: http://www.tktx.com/ Company News
On-Call: http://www.prnewswire.com/comp/120657.html
Copyright
Transkaryotic Therapies (NASDAQ:TKTX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Transkaryotic Therapies (NASDAQ:TKTX)
Historical Stock Chart
From Jul 2023 to Jul 2024